Evaluation of reactive blue 2 derivatives as selective antagonists for P2Y receptors

被引:17
作者
Brown, J [1 ]
Brown, CA
机构
[1] Univ Keele, Sch Life Sci, Keele ST5 5BJ, Staffs, England
[2] Wolverhampton Univ, Sch Appl Sci, Div Biomed Sci, Wolverhampton WV1 1SB, England
关键词
bovine aortic endothelial cells; P2Y(1); P2Y(2); antagonists; reactive blue 2; acid blue 129;
D O I
10.1016/S1537-1891(03)00030-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
P2Y receptor pharmacology is hampered by a lack of subtype selective antagonists. However, a recent study evaluated series of compounds, structurally related to the dye reactive blue 2, for their antagonist selectivity at P2X vs. P2Y receptors. Acid blue 129, acid blue 80, acid blue 25 and acid violet 34 were found to be the most potent of the antagonists studied, at P2Y receptors [Naunyn Schmiedeberg's Arch. Pharmacol. 357 (1998) 111]. In this study, we have determined the ability of these four agents to selectively antagonize inositol phosphate turnover mediated by P2Y(1) and P2Y(2) receptors that are natively expressed in bovine aortic endothelial (BAE) cells. Acid blue 129, acid blue 80, and acid violet 34 shifted the dose-response curve of the P2Y(1) agonist 2-methylthio adenosine trisphosphate (2MeSATP) to the right. Acid blue 129 and acid blue 80 were also very weak antagonists of the P2Y(2) agonist uridine 5'-triphosphate (UTP). At 30 and 100 muM, acid violet 34 failed to have any significant effect on the dose-response to UTP. However, at 10 muM, acid violet 34 enhanced the UTP responses. Acid blue 80, acid blue 129 and acid violet 34 are P2Y vs. P2X selective, but show poor selectivity between P2Y, and P2Y(2) receptors and are therefore of limited use in the field of P2Y receptor pharmacology. Furthermore, contrary to previous reports, acid blue 25 is not a P2Y-selective antagonist. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:309 / 315
页数:7
相关论文
共 35 条
[1]  
ALLSUP DJ, 1990, MOL PHARMACOL, V38, P84
[2]   COMPARATIVE-STUDIES ON THE AFFINITIES OF ATP DERIVATIVES FOR P-2X-PURINOCEPTORS IN RAT URINARY-BLADDER [J].
BO, XN ;
FISCHER, B ;
MAILLARD, M ;
JACOBSON, KA ;
BURNSTOCK, G .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 112 (04) :1151-1159
[3]   Molecular cloning and characterization of a novel ATP P2X receptor subtype from embryonic chick skeletal muscle [J].
Bo, XN ;
Schoepfer, R ;
Burnstock, G .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (19) :14401-14407
[4]   The regulation of vascular function by P2 receptors: multiple sites and multiple receptors [J].
Boarder, MR ;
Hourani, SMO .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1998, 19 (03) :99-107
[5]   2-chloro N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′,5′-bisphosphate is a selective high affinity P2Y1 receptor antagonist [J].
Boyer, JL ;
Adams, M ;
Ravi, RG ;
Jacobson, KA ;
Harden, TK .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (08) :2004-2010
[6]   NEW STRUCTURAL MOTIF FOR LIGAND-GATED ION CHANNELS DEFINED BY AN IONOTROPIC ATP RECEPTOR [J].
BRAKE, AJ ;
WAGENBACH, MJ ;
JULIUS, D .
NATURE, 1994, 371 (6497) :519-523
[7]   PPADS - AN ANTAGONIST AT ENDOTHELIAL P-2Y-PURINOCEPTORS BUT NOT P-2U-PURINOCEPTORS [J].
BROWN, C ;
TANNA, B ;
BOARDER, MR .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 116 (05) :2413-2416
[8]   Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: A comparison with the human bladder cancer derived epithelial cell line t24/83 [J].
Brown, J ;
Reading, SJ ;
Jones, S ;
Fitchett, CJ ;
Howl, J ;
Martin, A ;
Longland, CL ;
Michelangeli, F ;
Dubrova, YE ;
Brown, CA .
LABORATORY INVESTIGATION, 2000, 80 (01) :37-45
[9]  
BULTMANN R, 1994, N-S ARCH PHARMACOL, V349, P74
[10]   P-2-purinoceptor antagonists .3. Blockade of P-2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin [J].
Bultmann, R ;
Wittenburg, H ;
Pause, B ;
Kurz, G ;
Nickel, P ;
Starke, K .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1996, 354 (04) :498-504